Abstract 3323
Background
Innovative approaches are needed to translate molecular opportunities into clinical care. MoST tests a novel paradigm for evaluation of biomarker-driven treatments (tx) for patients (pts) with advanced cancer, with a particular focus on rare or neglected cancers.
Trial design
Tx-refractory pts (N = 1000) undergo molecular screening using archival tumour tissue. Results are reviewed by the Molecular Tumor Board (MTB) to identify actionable variants and eligibility for substudies. A master protocol allows expedited addition of ≥ 12 open-label, phase Ib/IIa, single-arm substudies, with 16 pts per module deemed reasonable for signal-seeking purposes. The primary objectives are to identify potential clinical activity for biomarker-driven tx, biomarkers that predict for response, and to evaluate the MoST study design. Three substudies are active: 1) palbociclib - molecular eligibility includes amplification/activating mutations in cyclin D pathway genes, or loss of function mutations in CDKN2A; 2) olaparib+durvalumab (ola+durva) – molecular eligibility is a homologous recombination repair gene defect; 3) durvalumab+tremelimumab (durva+treme) offers a tx in the absence of actionable findings. Further substudies planned include vismodegib and eribulin for tumours with PTCH1 or SMO mutations, and CD31 positivity respectively. Since September 2016, recruitment to screening has exceeded targets. Of the 571 pts enrolled to April 2018, 474 MTB reports have been issued, 57 are in progress, 31 had insufficient tissue and 43 died prior to issue of a MTB report. Median time to MTB report issue was 44 days over latest quarter (n = 89). Rare cancers comprise at least 44%; an actionable mutation to inform therapy reported in > 40%. Palbociclib (n = 16) and durva+treme (n = 4x16, 64 pts) substudies have completed recruitment; ola+durva (n = 3x16 pts) is currently recruiting. The distribution of actionable mutations across cancers, and in particular rare cancers will be informative, as it comprises the essential first steps to gaining access to novel, personalized treatments for pts.
Clinical trial identification
Framework protocol Trial ID ACTRN12616000908437. Registered 08 July 2016. Therapeutic substudy 1 (palbociclib) Trial ID ACTRN12616000931471. Registered 13 July 2016. Therapeutic substudy 2-5 (durvalumab plus tremelimumab) Trial ID ACTRN12616001019493. Registered 02 August 2016. Therapeutic substudy 6-8 (olaparib plus durvalumab) Trial ID ACTRN12617001000392. Registered 11 July 2017.
Legal entity responsible for the study
Human Research Ethics Committee, St Vincent’s Hospital; approval reference: HREC/16/SVH/23. Coordinating Centre for Molecular Screening: Garvan Institute of Medical Research, Darlinghurst NSW 2010. Coordinating Centre for Therapeutic Substudies: NHMRC Clinical Trials Centre, Camperdown NSW 2050.
Funding
The NSW Office for Health and Medical Research, granted 2/3/15: H15/13965 Therapeutic substudies to date have been funded by AstraZeneca Australia and Pfizer, which includes drug supply.
Editorial Acknowledgement
Not applicable.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract